DAVID T MILLER
Medical Practice at Smt Vw Dr, Brentwood, TN
License number
Florida 107014
Issued Date
Apr 28, 2010
Effective Date
Feb 18, 2016
Expiration Date
Jan 31, 2014
Category
Health Care
Type
Medical Doctor
Address
Address
201 Summit View Dr STE 100, Brentwood, TN 37027
Personal information
See more information about DAVID T MILLER at radaris.comName
Address
Phone
500 Mcearl Ln, Reagan, TN 38368
Spring City, TN
White House, TN
Smyrna, TN
Professional information
See more information about DAVID T MILLER at trustoria.com
Dr. David Miller, Brentwood TN - MD (Doctor of Medicine)
Dr. David Miller, Brentwood TN - MD (Doctor of Medicine)
Specialties:
Blood Banking & Transfusion Medicine
Address:
Integrated Oncology
201 Summit View Dr SUITE 100, Brentwood 37027
(615) 370-8393 (Phone)
201 Summit View Dr SUITE 100, Brentwood 37027
(615) 370-8393 (Phone)
Languages:
English
Education:
Medical School
University of Nebraska / College of Medicine
University of Nebraska / College of Medicine
David Thomas Miller, Brentwood TN
David Thomas Miller, Brentwood TN
Specialties:
Pathologist
Address:
201 Summit View Dr, Brentwood, TN 37027
Assay For Toxin Induced Neuronal Degeneration And Viability In C. Elegans
Assay For Toxin Induced Neuronal Degeneration And Viability In C. Elegans
US Patent:
2003002, Jan 30, 2003
Filed:
Jun 22, 2001
Appl. No.:
09/888233
Inventors:
Randy Blakely - Brentwood TN, US
Richard Nass - Nashville TN, US
David Miller - Brentwood TN, US
Richard Nass - Nashville TN, US
David Miller - Brentwood TN, US
International Classification:
A01K067/033, G01N033/00
US Classification:
800/009000, 800/013000
Abstract:
Provided are in vivo screening methods to detect and identify substances that affect neuronal viability, and/or prevent neurodegeneration, and/or confer neuroprotective effects. The screening methods utilize recombinant expressing a detectable marker in neuronal sub-groups and the use of neurotoxins specific to specific neuronal cells. Also provided are methods for identifying modulators of neurotransmitter transporters such as the dopamine transporter. Therefore, the invention provides methods for identifying substances that can be used in the prevention and therapy of neurodegenerative diseases.
Determining Protein Function In Cell Culture Using Rna Interference
Determining Protein Function In Cell Culture Using Rna Interference
US Patent:
2002018, Dec 5, 2002
Filed:
May 24, 2002
Appl. No.:
10/155909
Inventors:
Kevin Strange - Franklin TN, US
Michael Christensen - Salt Lake City UT, US
David Miller - Brentwood TN, US
Michael Christensen - Salt Lake City UT, US
David Miller - Brentwood TN, US
Assignee:
Vanderbilt University
International Classification:
C12Q001/68, C12Q001/00
US Classification:
435/004000, 435/006000
Abstract:
The present invention addresses one of the major issues in molecular biology today, “functional genomics.” The inventors have provided methods that utilize the phenomenon of RNA interference as a tool for identifying cDNAs that encode proteins with assayable function.
Assay For Toxin Induced Neuronal Degeneration And Viability In C. Elegans
Assay For Toxin Induced Neuronal Degeneration And Viability In C. Elegans
US Patent:
2005016, Jul 21, 2005
Filed:
Jan 5, 2005
Appl. No.:
11/029895
Inventors:
Randy Blakely - Brentwood TN, US
Richard Nass - Nashville TN, US
David Miller - Brentwood TN, US
Richard Nass - Nashville TN, US
David Miller - Brentwood TN, US
International Classification:
A01K067/033
US Classification:
800003000, 800008000
Abstract:
Provided are in vivo screening methods to detect and identify substances that affect neuronal viability, and/or prevent neurodegeneration, and/or confer neuroprotective effects The screening methods utilize recombinant expressing a detectable marker in neuronal sub-groups and the use of neurotoxins specific to specific neuronal cells. Also provided are methods for identifying modulators of neurotransmitter transporters such as the dopamine transporter. Therefore, the invention provides methods for identifying substances that can be used in the prevention and therapy of neurodegenerative diseases.
Quantitative Zap-70 Assay
Quantitative Zap-70 Assay
US Patent:
2007008, Apr 19, 2007
Filed:
Oct 14, 2005
Appl. No.:
11/251271
Inventors:
Keith Shults - Nolensville TN, US
Angel Flye - Chapel Hill TN, US
Leigh Hobbs - Brentwood TN, US
David Miller - Brentwood TN, US
Angel Flye - Chapel Hill TN, US
Leigh Hobbs - Brentwood TN, US
David Miller - Brentwood TN, US
International Classification:
G01N 33/574
US Classification:
435007230
Abstract:
An quantitative ZAP-70 assay is provided, with ZAP-70+ and ZAP-70− controls, normal human blood controls, an improved antibody with better signal to noise ratio, and using the median MEFL that is calibrated using a standard curve.
Quantitative Zap-70 Assay
Quantitative Zap-70 Assay
US Patent:
2011002, Jan 27, 2011
Filed:
Jul 19, 2010
Appl. No.:
12/838906
Inventors:
Keith E. Shults - Nolensville TN, US
Angel L. Flye - Chapel Hill TN, US
Leight Ann Hobbs - Brentwood TN, US
David Miller - Brentwood TN, US
Angel L. Flye - Chapel Hill TN, US
Leight Ann Hobbs - Brentwood TN, US
David Miller - Brentwood TN, US
International Classification:
G01N 33/574
US Classification:
435 723
Abstract:
An quantitative ZAP-70 assay is provided, with ZAP-70+ and ZAP-70− controls, normal human blood controls, an improved antibody with better signal to noise ratio, and using the median MEFL that is calibrated using a standard curve.